Back to Report Store Home

Frontier Pharma: Type 2 Diabetes Mellitus – GPCRs and Protein Kinases Dominate Pipeline, with Most Promising First-in-Class Targets Demonstrating Potential Disease-Modifying Effects

  • Published: Dec-2016
  • Report Code: GBIHC417MR
  • Report Format: pdf


Type 2 diabetes mellitus (T2DM) is a chronic, progressive and serious metabolic disorder characterized by hyperglycemia (high blood glucose levels) and associated with numerous complications and co-morbidities, including cardiovascular, renal and neurodegenerative diseases.

Global prevalence of the disease has risen rapidly in the past several decades, primarily as a result of rising obesity, a major risk factor for T2DM. This has resulted in a large and competitive market landscape, with a number of drugs competing with one another for different market segments, across multiple lines of therapy.

The emergence over the past decade of glucagon-like peptide-1 (GLP-1) receptor agonists, dipeptidyl peptidase 4 (DPP-4) inhibitors and sodium–glucose cotransporter 2 (SGLT-2) inhibitors has intensified competition. These new drug classes have been highly commercially successful and are now well established within the treatment algorithm.

In spite of these developments, there are still significant unmet needs for T2DM, and the rationale for investment in first-in-class innovation remains strong. First-in-class products account for a considerable proportion of the large T2DM pipeline, with a diverse range of first-in-class targets identified.


  • The escalating T2DM public healthcare need has resulted in a competitive market landscape

  • What is the pathophysiology of T2DM?

  • What are the common co-morbidities and complications?

  • How has the emergence of new drug classes in the past decade impacted the treatment algorithm?

  • What are the most significant unmet needs within the market?

  • The T2DM pipeline is large and innovative

  • Which molecule types and molecular targets are most prominent within the pipeline?

  • Which first-in-class targets are most promising?

  • How does the ratio of first-in-class targets to first-in-class products differ by stage of development and molecular target class?

  • The T2DM deals landscape is highly active

  • Do T2DM products attract high deal values?

  • Which molecule types and molecular targets dominate the deals landscape?

  • Which first-in-class pipeline products have no prior involvement in licensing or co-development deals?

Reasons To Buy

  • This report will allow you to:

  • Appreciate the current clinical and commercial landscapes by considering disease pathogenesis, etiology, epidemiology, symptoms, co-morbidities and complications, and treatment options.

  • Identify leading products and companies within the market, as well as key unmet needs, in order to gain a competitive understanding of gaps in the current market.

  • Recognize innovative pipeline trends by analyzing therapies by stage of development, molecule type and molecular target.

  • Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, all first-in-class targets in the T2DM pipeline have been assessed and ranked according to clinical potential. Promising early-stage targets have been further reviewed in greater detail.

  • Consider first-in-class pipeline products with no prior involvement in licensing and co-development deals that may represent potential investment opportunities.

License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
Email to a colleague Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments